Innate Pharma S.A. is a biotechnology company based in France focused on developing immunotherapy treatments for cancer. Its lead product candidate, IPH4102, targets the treatment of hematological malignancies, leveraging its proprietary platform to enhance immune responses against tumors.
Business Overview
Innate Pharma primarily generates revenue through partnerships and collaborations with larger pharmaceutical companies, leveraging its innovative drug candidates in exchange for upfront payments, milestones, and royalties. The company has a strong pipeline, which provides potential for future revenue streams as products advance through clinical trials.
Clinical trial results for IPH4102 and other pipeline candidates
Partnership announcements with larger pharmaceutical companies
Regulatory approvals from health authorities
Market sentiment towards biotechnology sector trends
Risk Factors
Regulatory changes impacting drug approval processes
Technological disruption in drug development methodologies
Emergence of new therapies that could outperform Innate's pipeline
Increased competition from established pharmaceutical companies in immunotherapy
High cash burn rate leading to potential liquidity issues
Dependence on external funding for continued operations
Macro Sensitivity
low - The biotechnology sector is generally less sensitive to economic cycles, as demand for healthcare and innovative treatments remains relatively stable regardless of economic conditions.
Moderate - Rising interest rates can increase the cost of capital for biotech firms, impacting funding for R&D and potentially affecting valuations, especially for companies without current revenue.
minimal - Innate Pharma has a negative debt/equity ratio, indicating minimal reliance on debt financing.
Profile
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector may find Innate Pharma appealing due to its innovative pipeline.
high - The stock has historically exhibited high volatility, reflecting the uncertainties inherent in biotech development.
Explore More
Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
